Black Rock Inc. Applied Molecular Transport Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$0.16 - $0.34 $7,748 - $16,464	-48,426 Reduced 9.59%	456,409 $73,000
Q2 2023 Aug 11, 2023	SELL	$0.24 - $0.37 $20,069 - $30,940	-83,622 Reduced 14.21%	504,835 $131,000
Q1 2023 May 12, 2023	SELL	$0.32 - $0.68 $629 - $1,338	-1,968 Reduced 0.33%	588,457 $188,000
Q4 2022 Feb 13, 2023	SELL	$0.35 - $1.26 $73,619 - $265,028	-210,340 Reduced 26.27%	590,425 $247,000
Q3 2022 Nov 14, 2022	SELL	$1.12 - $3.12 $179,985 - $501,387	-160,701 Reduced 16.71%	800,765 $780,000
Q2 2022 Aug 12, 2022	SELL	$2.76 - $7.65 $3.01 Million - $8.35 Million	-1,092,106 Reduced 53.18%	961,466 $2.8 Million
Q1 2022 May 12, 2022	BUY	$5.63 - $13.88 $642,540 - $1.58 Million	114,128 Added 5.88%	2,053,572 $15.4 Million
Q4 2021 Feb 10, 2022	BUY	$13.23 - $26.05 $847,169 - $1.67 Million	64,034 Added 3.41%	1,939,444 $27.1 Million
Q3 2021 Nov 09, 2021	BUY	$25.87 - $46.61 $2.75 Million - $4.95 Million	106,179 Added 6.0%	1,875,410 $48.5 Million
Q2 2021 Aug 11, 2021	BUY	$39.76 - $64.31 $70.3 Million - $114 Million	1,769,231 New	1,769,231 $80.9 Million

9.42K

Ticker AMTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,900,600
Description
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of r...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.